WORLDSymposium 2027 names three award honorees
WORLDSymposium 2027 will honor three leaders in lysosomal disease research, innovation, and patient advocacy when the meeting convenes Jan. 31-Feb. 4, 2027, in San Diego. Registration is open, with early rates ending Dec. 18 and the hotel block nearly full.
Why it matters: - WORLDSymposium uses its annual awards to spotlight people advancing gene therapy, clinical research, and patient advocacy in lysosomal diseases. - The 2027 meeting also gives researchers a venue to present late-breaking science and emerging clinical data to a global audience.
What happened: - WORLDSymposium announced three 2027 award recipients ahead of its 23rd annual meeting in San Diego. - The meeting will run Jan. 31-Feb. 4, 2027, at the Manchester Grand Hyatt San Diego. - Registration is now open for the international scientific meeting. - The Catalyst Award will go to Karen Pignet. - The Roscoe O. Brady Award will go to Cynthia J. Tifft, MD, PhD. - The Patient Advocate Leader Award will go to Daniel Lewi.
The details: - Karen Pignet founded Lysogene after her daughter was diagnosed with Sanfilippo syndrome. - Pignet helped lead an investigational gene therapy for Sanfilippo syndrome type A into an international Phase III clinical trial. - Pignet later founded Blue Daisy, a nonprofit that took over the program to bring the trial to completion. - Cynthia J. Tifft is a Senior Clinician and Deputy Clinical Director at the National Human Genome Research Institute. - Tifft directs the Pediatric Undiagnosed Diseases Program, which has coordinated evaluation of nearly 600 children with long-elusive diagnoses. - Tifft’s natural history research in glycosphingolipid and glycoprotein disorders has expanded understanding of those conditions. - Tifft and her team launched the first-in-human gene therapy trial in 2019 for Type I and Type II GM1 gangliosidosis. - Daniel Lewi co-founded and leads the Cure & Action for Tay-Sachs (CATS) Foundation. - Lewi founded the UK charity in 2011 and built it into an internationally recognized patient organization. - Lewi has supported patient registries, clinical research, and collaboration across the European and global GM2 gangliosidoses community. - WORLDSymposium will present the Catalyst Award at the Be The Catalyst event on Jan. 31. - WORLDSymposium will present the Roscoe O. Brady Award on Feb. 1. - WORLDSymposium will present the PAL Award on Feb. 2. - The meeting will include five days of scientific sessions, poster presentations, and collaborative discussions. - WORLDSymposium says the event brings together more than 2,000 researchers, clinicians, patient advocates, and industry professionals from over 50 countries. - Early registration rates end Dec. 18, 2026, and the hotel room block is almost sold out. - The Call for Late-Breaking Abstracts is open through Dec. 1, 2026. - The meeting website is worldsymposia.org.
Between the lines: - The honorees reflect WORLDSymposium’s focus on linking lab science, clinical development, and patient input in rare disease research. - The late-breaking session suggests the meeting is positioning itself as a venue for new data that can quickly shape study design and care decisions. - The mix of a biotech founder, a physician-scientist, and a patient advocate points to a broad definition of leadership in the lysosomal disease field.
What's next: - Investigators can submit late-breaking abstracts through Dec. 1, 2026. - Attendees can still register before early rates expire on Dec. 18, 2026. - The awards will be formally presented during the Feb. 1-4, 2027 meeting in San Diego.
The bottom line: - WORLDSymposium 2027 is leaning on awards, new science, and a large international turnout to push lysosomal disease research and patient care forward.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Health Professional Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.